Skip to main content

Table 1 Baseline characteristics of different antithrombotic treatment groups with a total of 671 patients included between January 2016 and October 2019 at ICUs of 12 clinical sites: (1) intravenous unfractionated heparin (iUFH, prophylactic dosage), (2) iUFH (therapeutic dosage), (3) antiplatelet therapy (aspirin (100 mg/day) and/or P2Y12 receptor inhibitor, i.e. clopidogrel (75 mg/day), prasugrel (10 mg/day) or ticagrelor (90 mg twice daily)) with iUFH (prophylactic or therapeutic dosage) except for triple therapy and (4) triple therapy (DAPT including aspirin (100 mg/day) and a P2Y12 receptor inhibitor with iUFH in therapeutic dosage)

From: Percutaneous dilatational tracheotomy in high-risk ICU patients

Treatment group (I) Heparin (prophylactic dosage)
(n = 101)
(II) Heparin (therapeutic dosage)
(n = 131)
(III) Aspirin and/or P2Y12 receptor inhibitor with Heparin (prophylactic or therapeutic dosage) except for triple therapy (n = 290) (IV) DAPT with heparin (therapeutic dosage) (triple therapy) (n = 149) Overall
(n = 671)
Age [years] mean ± SD 55 ± 16 64 ± 13 66 ± 12 70 ± 12 65 ± 14
Gender [male] n (%) 56 (55) 80 (61) 208 (72) 99 (66) 444 (66)
Body mass index [kg/m2] mean ± SD 26.02 ± 5.67 27.87 ±  + 5.39 27.16 ±  + 5.27 26.99 ± 4.68 27.08 ± 5.25
Reason for hospitalization
 Acute respiratory failure (ARDS, COPD, pneumonia) n (%) 38 (38) 32 (24) 43 (15) 6 (4) 119 (18)
 Sepsis n (%) 12 (12) 11 (8) 9 (3) 7 (5) 39 (6)
 Acute myocardial infarciation n (%) 0 (0) 0 (0) 78 (27) 77 (52) 155 (23)
 Shock (cardiogenic/septic/ hemorrhagic) n (%) 28 (28) 34 (26) 48 (17) 23 (15) 133 (20)
Others n (%) 23 (23) 54 (41) 112 (39) 36 (24) 225 (34)
Hypertension n (%) 49 (49) 78 (60) 212 (73) 116 (78) 455 (68)
Diabetes mellitus n (%) 15 (15) 38 (29) 89 (31) 55 (37) 197 (29)
Current smoker n (%) 19 (19) 34 (26) 101 (35) 42 (28) 196 (29)
Chronic kidney disease n (%) 24 (24) 54 (41) 90 (31) 50 (34) 219 (33)
Previous stroke n (%) 5 (5) 14 (11) 42 (14) 21 (14) 82 (12)
Atrial fibrillation n (%) 8 (8) 90 (69) 107 (37) 105 (70) 310 (46)
Aspirin n (%) 0 0 266 (92) 149 (100) 415 (62%)
P2Y12 inhibitor n (%) 0 0 138 (48) 149 (100) 287 (43%)
Creatinine [mg/dl] mean ± SD 1.38 ± 0.87 1.63 ± 0.95 1.60 ± 0.94 1.52 ± 0.85 1.57 ± 0.95
Hemoglobin [g/dl] mean ± SD 9.26 ± 1.55 9.28 ± 1.75 9.28 ± 1.46 9.34 ± 1.33 9.29 ± 1.51
Platelet count [G/l] mean ± SD 216 ± 150 222 ± 131 212 ± 131 249 ± 130 223 ± 134
INR mean ± SD 1.21 ± 0.42 1.23 ± 0.33 1.17 ± 0.30 1.24 ± 0.25 1.20 ± 0.32
aPTT [s] mean ± SD 37.99 ± 15.68 48.65 ± 22.96 39.10 ± 14.15 47.66 ± 16.82 42.68 ± 17.58
  1. All displayed laboratory values were recorded on the day of PDT 4 h prior to procedure. ARDS acute respiratory distress syndrome, COPD chronic obstructive pulmonary disease, INR International Normalized Ratio, aPTT activated Partial Thromboplastin Time, SD standard deviation